At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BHVN Biohaven Pharmaceutical Holding Co Ltd.
Trading 10-16 10:19:45 EDT
11.12
-0.31
-2.71%
High11.40Low10.99Vol142.92K
Open11.40D1 Closing11.43Amplitude3.63%
Mkt Cap1.67BTradable Cap1.31BTotal Shares150.42M
T/O1.59MT/O Rate0.12%Tradable Shares117.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biohaven Licenses IgG Degraders to Ono Pharma for Japan, Select Asian Markets
Reuters  ·  05:20
Biohaven Licenses IgG Degraders to Ono Pharma for Japan, Select Asian Markets
Analysts’ Top Healthcare Picks: Biohaven Ltd. (BHVN), Clover Health Investments (CLOV)
TIPRANKS  ·  10-09
Analysts’ Top Healthcare Picks: Biohaven Ltd. (BHVN), Clover Health Investments (CLOV)
Biohaven (BHVN), What Is Behind The Fresh Attention?
Simply Wall St.  ·  10-09
Biohaven (BHVN), What Is Behind The Fresh Attention?
Biohaven enters strategic licensing, collaboration pact with Ono Pharmaceutical
TIPRANKS  ·  10-08
Biohaven enters strategic licensing, collaboration pact with Ono Pharmaceutical
Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
MT Newswires Live  ·  10-08
Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
Biohaven Licenses MoDE IgG Degrader Portfolio to Ono Pharma in Japan, South Korea, Taiwan, ASEAN for up to USD 100 Million
Reuters  ·  10-08
Biohaven Licenses MoDE IgG Degrader Portfolio to Ono Pharma in Japan, South Korea, Taiwan, ASEAN for up to USD 100 Million
Ono Pharmaceutical Co., Ltd.: Will Pay Biohaven $80 Mln as an Upfront Payment and $20 Mln as a Milestone Achievement Payment, and Royalties of Approximately 20% on Net Sales
THOMSON REUTERS  ·  10-08
Ono Pharmaceutical Co., Ltd.: Will Pay Biohaven $80 Mln as an Upfront Payment and $20 Mln as a Milestone Achievement Payment, and Royalties of Approximately 20% on Net Sales
Ono Pharmaceutical Co., Ltd.: Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize Igg Degraders in Japan, South Korea, Taiwan, and Asean
THOMSON REUTERS  ·  10-08
Ono Pharmaceutical Co., Ltd.: Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize Igg Degraders in Japan, South Korea, Taiwan, and Asean
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular Igg Degraders in Japan and Select Asian Regions, Lead Candidate Bhv-1300 in Phase 3 for Graves' Disease
THOMSON REUTERS  ·  10-08
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular Igg Degraders in Japan and Select Asian Regions, Lead Candidate Bhv-1300 in Phase 3 for Graves' Disease
Biohaven - to Receive up to $100 Mln Payments and 20% Royalties from Ono
THOMSON REUTERS  ·  10-08
Biohaven - to Receive up to $100 Mln Payments and 20% Royalties from Ono
Biohaven - Ono Obtains Exclusive License for Biohaven's Igg Degraders in Japan, South Korea, Taiwan, Asean
THOMSON REUTERS  ·  10-08
Biohaven - Ono Obtains Exclusive License for Biohaven's Igg Degraders in Japan, South Korea, Taiwan, Asean
Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says
MT Newswires Live  ·  09-18
Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says
Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.
Dow Jones  ·  09-18
Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.
Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.
Dow Jones  ·  09-11
Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.
Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-11
Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
TIPRANKS  ·  09-11
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
TIPRANKS  ·  09-10
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
Biohaven falls -15.3%
TIPRANKS  ·  09-10
Biohaven falls -15.3%
U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven
Reuters  ·  09-10
U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven
Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data
Reuters  ·  09-10
Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data
No data available

Introduction

Company Name.
Biohaven Pharmaceutical Holding Co Ltd.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Issue price:
--